RTP Mobile Logo
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of ER-Positive Breast Cancer (Webinar Video Proceedings)
Released January 2022

Featuring perspectives from Drs Aditya Bardia, Kevin Kalinsky and Joyce O’Shaughnessy, moderated by Dr Erika Hamilton. Published January 14, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.


    • Evaluate the results of genomic assays and other relevant patient- and treatment-related factors to personalize the use of adjuvant systemic therapy for individuals with newly diagnosed ER-positive, HER2-negative, lymph node-negative and node-positive breast cancer.
    • Recall available Phase III data documenting the benefit of abemaciclib in combination with standard hormonal therapy for patients with ER-positive, HER2-negative localized breast cancer at high risk for recurrence, and consider the implications of these findings for clinical care.
    • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed ER-positive metastatic breast cancer (mBC), considering clinical presentation, prior treatment course and psychosocial status.
    • Appraise available research data with the use of commercially available CDK4/6 inhibitors for the treatment of ER-positive mBC, and optimally incorporate these agents into the care of appropriate patients.
    • Recognize the frequency of phosphoinositide 3-kinase pathway mutations in ER-positive mBC, and understand the FDA-approved indication for alpelisib in combination with fulvestrant to optimally employ this approach for patients with ER-positive, HER2-negative disease harboring a PIK3CA mutation.
    • Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for ER-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 2 (Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SABCS2021/ERPosBC/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY AND MODERATOR — The following faculty reported relevant financial relationships with ineligible entities:


    Aditya Bardia, MD, MPH
    Director, Breast Cancer Research Program
    Associate Professor
    Harvard Medical School
    Attending Physician
    Massachusetts General Hospital
    Boston, Massachusetts

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Daiichi Sankyo Inc, Foundation Medicine, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, Merck, Novartis, Pfizer Inc, Phillips HealthCare Services Ltd, Puma Biotechnology Inc, Radius Health Inc, Sanofi Genzyme, Taiho Oncology Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Merck, Novartis, Pfizer Inc, Radius Health Inc, Sanofi Genzyme.

    Kevin Kalinsky, MD, MS
    Associate Professor
    Department of Hematology and Medical Oncology
    Emory University School of Medicine
    Director, Glenn Family Breast Center
    Director, Breast Medical Oncology
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Cyclacel Pharmaceuticals Inc, Eisai Inc, Immunomedics Inc, Lilly, Merck, Novartis, Pfizer Inc, Seagen Inc; Speakers Bureau: Genentech, a member of the Roche Group, Immunomedics Inc.

    Joyce O’Shaughnessy, MD
    Celebrating Women Chair in Breast Cancer Research
    Baylor University Medical Center
    Director, Breast Cancer Research Program
    Texas Oncology
    US Oncology
    Dallas, Texas

    Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Grail Inc, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Myriad Genetic Laboratories Inc, Nektar, Novartis, Ontada, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Syndax Pharmaceuticals Inc, Synthon, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Speakers Bureau: Lilly, Pfizer Inc, Seagen Inc.


    Erika Hamilton, MD
    Director, Breast and Gynecologic Research Program
    Sarah Cannon Research Institute/Tennessee Oncology
    Nashville, Tennessee

    Advisory Committee and Consulting Agreements (to Institution): Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Deciphera Pharmaceuticals Inc, Eisai Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Lilly, Merck, Mersana Therapeutics Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Silverback Therapeutics; Contracted Research (to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Akesobio Australia Pty Ltd, Amgen Inc, ArQule Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Compugen, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dana-Farber Cancer Hospital, Deciphera Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, EMD Serono Inc, Fochon Pharmaceuticals Ltd, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Harpoon Therapeutics, Hutchison MediPharma, ImmunoGen Inc, Immunomedics Inc, Infinity Pharmaceuticals Inc, InventisBio, Karyopharm Therapeutics, Leap Therapeutics Inc, Lilly, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Merck, Mersana Therapeutics Inc, Merus BV, Molecular Templates, Novartis, NuCana, Olema Oncology, OncoMed Pharmaceuticals Inc, Onconova Therapeutics Inc, Orinove Inc, Pfizer Inc, PharmaMar, Plexxikon Inc, Polyphor, Puma Biotechnology Inc, Radius Health Inc, Regeneron Pharmaceuticals Inc, Rgenix, Seagen Inc, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, Stemcentrx, Sutro Biopharma, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Torque Therapeutics, Verastem Inc, Zenith Epigenetics, Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Exact Sciences, Lilly and Sanofi Genzyme.

    Release date: January 2022
    Expiration date: January 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):